Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor and Collaborators     
Celgene Corporation
Multiple Myeloma Research Consortium

Contact    
Bond V. Vo, PharmD, RPh
+ 1 (908) 673-9232     
clinicaltrialdisclosure@celgene.com  


Continue Reading

Investigator
Ye Hua, MD, MPH     
Celgene Corporation

ClinicalTrials.gov Identifier
NCT01497093